Controlled release composition and method of producing the same

Details Controlled release composition and method of producing the same Controlled release composition and method of producing the same

2008-09-30

2008-09-30

Tate, Christopher R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

10182731

ABSTRACT:
A controlled release composition containing a physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided.A controlled release composition comprising (1) a physiologically active substance or salt thereof in an amount of about 14% (w/w) to about 24% (w/w) based on the total composition weight, (2) hydroxynaphthoic acid selected from the group consisting of 3-hydroxy-2-naphthoic acid and 1-hydroxy-2-naphthoic acid or salt thereof, and (3) a lactic acid polymer or salt thereof having a weight-average molecular weight of 15000 to 50000 in which the content of polymers having molecular weights of 5000 or less is about 5% by weight or less, wherein the molar ratio of said hydroxynaphthoic acid or salt thereof to said physiologically active substance or salt thereof is from 3:4 to 4:3.

REFERENCES:
patent: 3297033 (1967-01-01), Schmitt et al.
patent: 3565869 (1971-02-01), DeProspero
patent: 3755558 (1973-08-01), Scribner
patent: 3773919 (1973-11-01), Boswell et al.
patent: 3839297 (1974-10-01), Wasserman et al.
patent: 3890283 (1975-06-01), Casey et al.
patent: 3912692 (1975-10-01), Casey et al.
patent: 4249531 (1981-02-01), Heller et al.
patent: 4258063 (1981-03-01), Chun et al.
patent: 4273920 (1981-06-01), Nevin
patent: 4479911 (1984-10-01), Fong
patent: 4539981 (1985-09-01), Tunc
patent: 4605730 (1986-08-01), Shalaby et al.
patent: 4652441 (1987-03-01), Okada et al.
patent: 4677191 (1987-06-01), Tanaka et al.
patent: 4728721 (1988-03-01), Yamamoto et al.
patent: 4767628 (1988-08-01), Hutchinson
patent: 4801739 (1989-01-01), Franz et al.
patent: 4849228 (1989-07-01), Yamamoto et al.
patent: 5594091 (1997-01-01), Igari et al.
patent: 5665394 (1997-09-01), Igari et al.
patent: 5763513 (1998-06-01), Suzuki et al.
patent: 5922682 (1999-07-01), Brich et al.
patent: 6113943 (2000-09-01), Okada et al.
patent: 6353086 (2002-03-01), Kolstad et al.
patent: 6565874 (2003-05-01), Dunn et al.
patent: 6699500 (2004-03-01), Okada et al.
patent: 6740634 (2004-05-01), Saikawa et al.
patent: 0 145 240 (1985-06-01), None
patent: 0 190 833 (1986-08-01), None
patent: 0 202 065 (1993-04-01), None
patent: 0 586 238 (1994-03-01), None
patent: 0 052 510 (1994-10-01), None
patent: 0 668 073 (1995-08-01), None
patent: 0 839 525 (1998-05-01), None
patent: 1 048 301 (2000-11-01), None
patent: 1 158 014 (2001-11-01), None
patent: 1 197 208 (2002-04-01), None
patent: 0 058 481 (2003-05-01), None
patent: 1 310 517 (2003-05-01), None
patent: 1 310 517 (2006-04-01), None
patent: 2 145 422 (1985-03-01), None
patent: 6-78425 (1994-10-01), None
patent: 7-278277 (1995-10-01), None
patent: 11-269094 (1999-10-01), None
patent: WO 95/15767 (1995-06-01), None
patent: WO 00/35990 (2000-06-01), None
patent: WO 01/05380 (2001-01-01), None
patent: WO 02/12369 (2002-02-01), None
patent: WO 02/43766 (2002-06-01), None
patent: WO 02/47722 (2002-06-01), None
Woo et al., “In Vitro Characterization and in Vivo Testosterone Suppression of 6-Month Release Poly(D,L-Lactide) Leuprolide Microspheres,”Pharmaceutical Research(Apr. 2002), vol. 19, No. 4, pp. 546-550, Plenum Publishing Corporation.
Beck et al., “Systemic and local delivery of contraceptive steroids using biodegradable microcapsules,” Progress in Contraceptive Delivery Systems, 1980, vol. 1, 63-81.
Braun et al., Praktical Macromolecular Organic Chemistry, 1966, any edition, 57-59 (English translation attached).
Brock, Thomas D., “Membrane Filtration, A User's Guide and Reference Manual,” Science Tech, Inc., 1983, 290-291.
Encyclopedic Handbook of Biomaterials and Bioengineering, Part A: Materials, vol. 2, 1995, 1014-1054.
Kulkami et al., “Biodegradable Poly(lactic acid) Polymers,” J. Biomed. Mater. Res., 1971, 5, 169-181.
Miller et al., “Degradation Rates of Oral Resorbable Implants (Polylactates and Polyglycolates): Rate Modification with Changes in PLA/PGA Copolymer Ratios,” J. Biomed. Mater. Res., 1977, 11, 711-719.
Pitt et al., “Sustained Drug Delivery Systems. I. The Permeability of Poly(ε-Caprolactone), Poly(DL-Lactic Acid), and Their Copolymers,” J. Biomed. Mater. Res., 1979, 13, 497-507.
Rompp Chemie Lexikon, Falbe et al., Ed., 1991 Georg Thieme Verlag, 3107-3108.
Schindler et al., “Biodegradable polymers for sustained drug delivery,” Contemporary Topics in Polymer Science, Eli M. Pearce et al., Ed., 1977, 2, pp. 251-289.
Suzuki et al., “Microencapsulation and Dissolution Properties of a Neuroleptic in a Biodegradable Polymer, Poly(d,l-lactide),” J. Pharm. Science, Jan. 1985, 74(1), 21-25.
Vert et al., “Bioresorbable Plastic Materials for Bone Surgery,” Macromolecular Biomaterials, 1984, Chapter 6, 119-142.
Vert, et al., “Stereoregular Bioresorbable Polyesters for Orthopedic Surgery,” Makromol. Chem. Suppl., 1981, 5, 30-41.
Woodland et al., “Long-Acting Delivery Systems for Narcotic Antagonists,” J. Med. Chem., 1973, 16(8), 897-901.
Rompp Chemie Lexikon, Falbe et al., Ed., 1991 Georg Thieme Verlag, 3107-3108, and English translation (4 pgs.).
Bittner et al., “Bovine serum albumin loaded poly(lactide-co-glycolide) microspheres: the influence of polymer purity on prticle characteristics,” J. Microencapsulation, 1998, 15(4):495-514.
Collins et al., “Isolation and Purification of Polymer,” Experiments in Polymer Science, 1973, pp. 62-69.
Eisenbach, Prof. Dr. Claus D., Expert Opinion of Apr. 4, 2006 in EP 1 310 517, 44 pages.
Psychrembel Klinisches Wörterbuch, 1994, 257, Ed., de Gruyter Ed., sections “BnRH” and “GnRH-Agonisten,” 3 pages.
Rote Liste, 2000, section 50 036 “Enantone,” section 50 038 “Kryptocur,” and section 50 039 “Lutrelef,” 3 pages.
Ruiz et al., “Influence of Average Molecular Weights of Poly(DL-Lactic Acid-Co-Glycolic Acid) Copolymers 50/50 on Phase Separation and in Vitro Drug Release from Microspheres,” Pharmaceutical Research, 1990, 7(9):928-934.
Schartel et al., “Dielectric and thermodynamic properties of biodegradable poly(D,L-lactide-co-glycolide) and the effect of the microencapsulation and release of captopril,” J. Microencapsulation, 1997, 14(4):475-788.
Taguchi et al., “Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study group,” Gan to Kagaku Ryoho, Mar. 1995, 22(4):495-508, with PubMed English Abstract, 15, pages.
The Merck Index, 1989, 11thEd., entry 4433 “Goserelin,” p. 711, 3 pages.
The Merck Index, 1989, 11thEd., entry 9662 “Triptoelin,” pp. 1533-1534, 4 pages.
The Merck Index, 2001, 13thEd., entry 5478, “Leuprolide,” 3 pages.

Affiliated with

Also associated with

Rating

Controlled release composition and method of producing the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Controlled release composition and method of producing the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release composition and method of producing the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3948157